Avenge Bio, Inc., a US-based biotechnology company, announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for AVB-001 in peritoneal malignancies.
AVB-001 is the first clinical application of the LOCOcyte platform, encapsulating cells designed to secrete native IL-2 in immune-activating alginate capsules. The first-in-human AVB-001 clinical trial will be an intraperitoneal administration to treat platinum resistance ovarian cancer.
The Phase one, multi-centre clinical trial is likely to commence in the second half of 2022 and is to assess the tolerability of the product, determine a recommended dose for Phase two, measure immunological changes in the blood and peritoneal environment, and evaluate anti-tumour activity.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML